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Abstract
Background: The indicating FTA card is a dry medium used for collection of cervical samples. HPVIR is a multiplex
real-time PCR test that detects 12 high-risk human papillomavirus types (hrHPV) and provides single genotype
information for HPV16, − 31, − 35, − 39, − 51, − 56, and − 59 and pooled type information for HPV18/45 and HPV33/
52/58. The aim of this study was to evaluate whether a strategy with cervical samples collected on the FTA card
and subsequently analysed with the HPVIR test complies with the criteria of the international guidelines for a
clinically validated method for cervical screening.
Methods: We performed a non-inferiority test comparing the clinical sensitivity and specificity of the candidate test
(FTA card and HPVIR) with a clinically validated reference test (Cobas® HPV test) based on liquid-based cytology
(LBC) samples. Two clinical samples (LBC and FTA) were collected from 896 participants in population-based
screening. For evaluation of the specificity we used 799 women without ≥ CIN2, and for clinical sensitivity we used
67 women with histologically confirmed ≥ CIN2. The reproducibility was studied by performing inter- and intra-
laboratory tests of 558 additional clinical samples.
Results: The clinical sensitivity and specificity for samples collected on the FTA card and analysed using the HPVIR
test were non-inferior to samples analysed with the Cobas® HPV test based on LBC samples (non-inferiority test
score, p = 1.0 × 10− 2 and p = 1.89 × 10− 9, respectively). Adequate agreement of > 87% was seen in both the intra-
and inter-laboratory comparisons.
Conclusions: Samples collected on the indicating FTA card and analysed with HPVIR test fulfil the requirements of
the international guidelines and can therefore be used in primary cervical cancer screening.
Keywords: HPV, DNA testing, Primary cervical cancer screening, International guidelines
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: ulf.gyllensten@igp.uu.se
1Department of Immunology, Genetics, and Pathology, Biomedical Center,
Science for Life Laboratory Uppsala, Uppsala University, Box 815, SE-75108
Uppsala, Sweden
Full list of author information is available at the end of the article
Gustavsson et al. Virology Journal          (2019) 16:107 
https://doi.org/10.1186/s12985-019-1216-7
Background
The use of HPV DNA tests is more effective in pri-
mary cervical cancer screening than cytology [1] and
national and international guidelines therefore recom-
mend transition to primary screening using HPV test
[2, 3]. Over the last decades, Hybrid Capture 2 (HC2,
QIAGEN, Germany) and GP5+/6 + −PCR EIA have
been the two most widespread HPV tests, and have
been clinically validated based on data from random-
ized control trials [1, 4]. However, a series of add-
itional HPV tests are available but have not been
clinically validated [5, 6]. In order to determine if a
candidate test fulfil the requirements with regard to
clinical sensitivity and specificity for detecting cervical
intraepithelial neoplasia grade 2 or worse (≥ CIN2),
international guidelines for validation of new tests
have been developed [2]. This validation also includes
intra-laboratory reproducibility and inter-laboratory
agreement. Several other HPV tests, in addition to
HC2 and GP5+/6 + −PCR EIA, have been clinically
validated according to these guidelines and recom-
mended for use in primary screening [7]. The most
common used clinically validated method for HPV
testing in screening is based on collection of LBC
samples and the Cobas® HPV test [8–10].
HPVIR is a laboratory developed (LDT), multiplex
real-time PCR test, detecting and quantifying HPV16,
18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 [11]. In this
application, a cervical or vaginal sample is applied on an
indicating FTA elute micro card™ [12–15] and left to dry
before storage. The clinical material applied to this card
is stable at room temperature and samples stored on
FTA cards for 1 year have shown identical HPV typing
results as compared to the use of liquid-based cytology
(LBC) collection media [16]. Several studies have shown
good agreement in HPV testing between samples applied
to the FTA card and samples stored in liquid-based
media [17, 18]. We have previously demonstrated con-
sistent HPV typing results across menstrual cycle phases
and calendar time using the FTA card for sample collec-
tion [13]. The HPVIR test is presently used in Uppsala
County, Sweden, as triage of women with ASCUS/CIN1
in cytology, and as ‘test of cure’ together with cytology 6
months after excisional treatment of CIN. Since 2008
more than 50,000 samples have been analysed using
HPVIR.
One advantage of using the FTA card is their suitabil-
ity for self-sampling, which represent an important de-
velopment of cervical cancer screening. Recently, we
have shown that repeated self-sampling on FTA cards is
as reliable for HPV testing as assisted sampling by a
midwife or gynaecologist [14, 15], and that this strategy
can result in detection of more than twice as many
women with ≥ CIN2 in histology as compared to
screening with cytology [14, 15]. In this study we have
validated our method of applying samples on the indi-
cating FTA card and using the HPVIR test according to
criteria of Meijer and co-workers [2], using collection of
LBC samples and the Cobas® HPV test as reference test.
Methods
Study population
For this study we invited 896 women who were sched-
uled for cervical cancer screening in Uppsala County
during 2017 and 2018. Among these, 819 women visited
a midwife surgery and performed a primary screening
test with both methods. Seven hundred ninety-nine
women were either HPV negative or had histologically
confirmed < CIN2 and were included in the comparison
between the candidate test and the reference test to as-
sess the clinical specificity. To determine the sensitivity,
we studied a cohort of 75 women scheduled for a col-
poscopy due to abnormal cytology or/and a positive
Cobas® HPV test in primary screening. Of these, 67
women with histologically confirmed ≥ CIN2 were in-
cluded in the analysis of sensitivity. The inclusion cri-
teria for all participants in the study were ≥ 30 years of
age and not hysterectomized, or pregnant.
The included women either had a midwife or a gy-
naecologist collecting two cervical samples per partici-
pant using one cytobrush for each collection. One
sample was applied to an indicating FTA elute micro
card™ (art. no WB129308, GE Healthcare, Longwood
Dr., Cardiff CF14 7YT, UK) and the other sample was
transferred to the liquid based medium (LBC) (Thin-
Prep, Hologic Inc., 250 Campus drive, Marlborough,
MA, U.S.A). Sampling was randomized, meaning that
the first sample was allocated randomly to either the
FTA card or the liquid based medium. The FTA card
sample was analysed using the HPVIR test (candidate
test) and the LBC sample using Cobas® HPV test (ref-
erence test) on the 4800 platform (Roche molecular
systems, 4300 Hacienda Dr., Pleasanton, CA 94588,
USA). Women with at least one HPV positive out-
come of the tests were referred for colposcopy and
biopsy. The study was approved by the regional ethics
committee in Uppsala, Sweden (Dnr 2017/088).
The inter-laboratory agreement and reproducibility
of the candidate test (FTA card and HPVIR test) was
determined using samples from 558 women, of which
284 (51%) had previously tested HPV positive using
the Hybrid Capture 2 (HC2) test. These samples were
originated from another cohort and collected in the
Nelson Mandela Hospital (WSU) or Mbekweni
Community Clinic, Eastern Cape, South Africa. One
sample was collected on the FTA card and the other
in a tube of liquid medium for HC2. The laboratory
at University of Cape Town (UCT) performed the
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evaluation of the inter-laboratory agreement. The
intra-laboratory reproducibility was studied by com-
parison of the results of two different research engi-
neers (Operators) in Uppsala, processing the same set
of 558 samples.
HPVIR test of FTA samples
FTA cards were processed using an automated labora-
tory system (easyPunch STARlet, Hamilton Robotics,
Via Crusch 8 CH-7402 Bonaduz, GR, Switzerland) where
a robot arm picked up each FTA card, took a photo-
graph of the sample deposition area, and then calculated
which part of the card that contained the highest con-
centration of cells using a machine learning software.
The robot first collected 5 punches from a clean card
area and thereafter it punched 4 circular pieces of 3 mm
diameter from the sample deposit area and collected all
4 punches in a single well in a 96-well microtiter plate.
DNA was then extracted as described earlier and the
HPV test was performed using the real-time PCR assay
HPVIR [11, 19]. The HPVIR test is LDT optimized for
the real-time PCR instrument Quantstudio 6 and 7 (Life
technologies, 5791 Van Allen Way, Carlsbad, CA 92008,
USA) together with specifically tested PCR reagents and
oligos. This test detects and quantifies a human single
copy gene (housekeeping gene), HMBS (Homo sapiens
hydroxymethylbilane synthase; GenBank accession no.
M95623.1) as a control that the sample contains enough
cellular material for the test to be informative. The test
also detects and quantifies HPV16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58 and 59, and provides single genotype in-
formation for all types except HPV18/45 and HPV33/
52/58, which are detected together as two groups. The
limit of detection (LOD) for HPVIR is 10 HPV copies
per PCR. In order for a sample to contain sufficient
amount of material for the HPV test to be informative, a
threshold of 10 copies of the nuclear single copy gene
per PCR is used [19].
Cobas® HPV test on LBC samples
Samples were collected in 20mL LBC medium and stored
in room temperature until analysed. The Cobas® 4800 is a
fully automated system for sample preparation and real-
time PCR, including the FDA approved Cobas® HPV test.
The Cobas® HPV test include 14 hrHPV (16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) of which HPV16
and 18 are detected as single genotypes while the others
types are reported as a group denoted ‘Other HPV’ types
(12 pooled types). To perform this assay, the 20mL tube
with cervical sample in LBC were loaded into the Cobas®
480 instrument, and 400 μL from each tube was trans-
ferred to the extraction plate, after which the samples
were lysed in the presence of a chaotropic reagent. The
DNA was then purified by adsorption to magnetic glass
particles, washed and eluted in 100 μL dH2O. Fifty micro-
liter of this was mixed with PCR reagents for amplification
in the Cobas® 480 instrument. All Cobas® tests were per-
formed by an accredited laboratory (UniLabs AB, Klinisk
molekylärbiologi, Skaraborgs sjukhus, Skövde, Sweden).
Hybrid capture® 2 assay on liquid-based samples
Samples for the Hybrid Capture® 2 assay (HC2) (Qiagen Str.
1, 40,724 Hilden, Germany) were collected and handled
according manufactures recommendations by the lab at
University of Cape Town (UCT). HC2 is based on
hybridization with RNA probes to detect 13 hrHPV (16, 18,
31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68). A cut-off value
of RLU/CO=1, is equivalent to 1 pg HPV DNA per mL
sampling buffer was used as a threshold for an HPV positive
test.
LINEAR ARRAY® HPV genotyping
Specimen that were positive with the Cobas® HPV test
and typed as ‘Other HPV‘but negative with HPVIR were
genotyped using the Roche LINEAR ARRAY® HPV
genotyping test (Roche molecular systems, 4300 Haci-
enda Dr., Pleasanton, CA 94588, USA). To this end, 5
mL ThinPrep LBC cervical cell material were centrifuged
at 5000 g for 30 min in 4 °C, and the cell pellet was re-
suspended in 400 μL phosphate-buffered saline. DNA
was extracted from resuspended cells using MagNA
Pure Compact (Roche) and the MagNA Pure Compact
Nucleic Acid Isolation Kit (Roche). HPV genotyping was
then performed using the Roche Linear Array HPV
genotyping test which identifies 37 different high- and
low-risk types (HPV6, 11, 16, 18, 26, 31, 33,35, 39, 40,
42, 44, 45, 51, 52, 53, 54, 56,58, 59, 61, 62, 64, 66, 67, 68,
69, 70, 71, 72, 73, 81, 82, 83, 84, 89 and IS39).
Colposcopy and pathology
All gynaecologic examinations of Swedish samples were
performed at the Clinic of Obstetrics and Gynaecology,
Uppsala University Hospital. A sample for cytological
analysis was also collected at the same visit. The
colposcopic evaluation included an identification of
squamocolumnar junction and transformation zone (TZ)
with application of 5% acetic acid and iodine solution.
Directed biopsies were obtained from all the identified
abnormal areas and a blind biopsy was taken in women
with normal colposcopy. All cytology and histology
samples were analysed at the Clinic of Pathology and
Cytology, Uppsala University Hospital, Uppsala. The
classification was according to SNOMED (Systematized,
Nomenclature of Medicine; College of American Pathol-
ogists, Skokie, IL, USA) and the highest histological
grade found in each patient was used for interpretation
of the results.
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Statistical analysis
Clinical specificity and sensitivity for samples on FTA
card analysed with HPVIR was compared with LBC sam-
ples analysed with the Cobas® HPV test, using a binomial
test for non-inferiority with a power of at least 80%, as
estimated in earlier studies [4, 20]. Non-inferiority was
defined as a relative sensitivity for ≥ CIN2 of 90%, and a
relative specificity for ≥ CIN2 of 98% [4]. In calculating
non-inferiority of the specificity, a positive response as
described in Tang et al. [20] was defined as a negative
test result. Confidence intervals for incidences, sensitiv-
ities and specificities were calculated using the modified
Wald method as described in Agresti et al. [21]. Kappa
values and confidence intervals for kappa values were
calculated using the GraphPad online calculator (https://
www.graphpad.com/quickcalcs/kappa1/). The thresholds
for intra-laboratory reproducibility and inter-laboratory
agreement were set to a lower confidence bound of
≥87% with kappa values > 0.5 as proposed by Meijer and
colleagues [4].
Results
Clinical specificity of the FTA card and HPVIR test
Two samples, the FTA card and LBC, were obtained
from 799 women (median age, 42 years, range 30–64
years) with no evidence of ≥ CIN2, and these were used
in the calculation of clinical specificity. Of the 799
women, the candidate and reference test agreed on 747
women to be HPV negative and 23 women to be HPV
positive, corresponding to an agreement of 96.4%
(Table 1). Among the 52 women whom were HPV posi-
tive by one or both of the assays, the median follow-up
time was 2.0 (range 0.5–4.3) months and 33% (17/52)
had normal histology, while 67% (35/52) had CIN1. The
incidence of HPV positive women was almost twice as
high using the Cobas® HPV test (6.1, 95% CI = 4.6–8.0%,
49/799) compared to using HPVIR (3.3, 95% CI = 2.2–
4.7%, 26/799). Among women that were positive only
with Cobas® HPV test, 42% (11/26) had normal histology
and 58% (15/26) had CIN1. The clinical specificity of
HPVIR was 96.8% (95% CI = 95.3–97.8) compared to
93.9% (95% CI = 92.0–95.3) for the Cobas® HPV test.
There was no statistical evidence that the clinical specifi-
city of HPVIR was inferior to that of the Cobas® HPV
test (T = 5.89, p = 1.89 × 10− 9).
Clinical sensitivity of the FTA card and HPVIR test
To estimate the clinical sensitivity, samples from 67
women ≥30 years (median age, 37 years, range, 30 to 57
years) with histologically confirmed ≥ CIN2 were used.
Among these, 23 women had CIN2 and 44 had ≥ CIN3
and the median follow-up time was 5.2 (range 0 to 42.2)
months. Among the 67 women, both tests agreed on 60
women to be HPV positive and none of the women to
be HPV negative (Table 1). Four women were HPV posi-
tive only with HPVIR and 3 women were HPV positive
only with the Cobas® HPV test. No woman was negative
by both tests. The agreement between the methods was
89.6% (60/67). The clinical sensitivity of HPVIR was
95.5% (95% CI = 87.2–99.0) and that of Cobas® HPV was
94.0% (95% CI = 85.2–98.1). In conclusion, there was no
statistical evidence that the clinical sensitivity of HPVIR
was inferior to that of Cobas® HPV test (T = 2.31, p =
1.04 × 10− 2).
Analysis of discordant samples
A set (n = 23) of the LBC samples that were HPV posi-
tive with ‘Other HPV’ using Cobas® HPV test but nega-
tive with HPVIR were analysed using the Roche LINEAR
ARRAY® HPV genotyping test. Of the 23 samples, the
linear array was negative for 2 samples, 2 samples had
only non-hrHPV types (53, HPV-CP6108, 62), another 2
samples contained both hrHPV and non-hrHPV (6, 54,
61, 62, 83) while the remaining 17 samples had one or
several of the following hrHPV 31, 33, 35, 39, 45, 52, 58,
59, 66, 68. Among the 23 samples, 6 contained only
HPV66 and/or HPV 68.
Intra-laboratory reproducibility and inter-laboratory
agreement
The intra-laboratory reproducibility and inter-laboratory
agreement were estimated using 558 samples, of which
284 were HPV positive by HC2 (51%). In Uppsala, two
research engineers (Operators) performed a blinded
intra-laboratory test. The reproducibility (kappa value)
between operators was estimated to 0.974 (95% CI =
0.956–0.993), with an agreement of 98.7% (Table 2). For
the inter-laboratory test samples were collected on the
Table 1 Comparison of the HPVIR and COBAS analysis
Cobas test
Sample type HPVIR test HPV positive HPV negative Total
Cases (≥CIN2) HPV positive 60 4 64
HPV negative 3 0 3
Total 63 4 67
Controls (<CIN2) HPV positive 23 3 26
HPV negative 26 747 773
Total 49 750 799
Table 2 Intra-laboratory reproducibility of the HVIR test
Uppsala Operator # 1
Uppsala Operator #2 HPV positive HPV negative Total
HPV positive 235 1 236
HPV negative 6 316 322
Total 241 317 558
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indicating FTA card and analysed by the HPVIR test at
the Uppsala and Cape Town laboratories. The inter-la-
boratory agreement between analyses performed in Upp-
sala and in Cape Town was 93.7%, with a kappa value of
0.874 (95% CI = 0.834–0.914) (Table 3).
Discussion
In this study we compared the clinical performance of
cervical samples applied on the FTA card and analysed
with HPVIR to LBC samples analysed with the Cobas®
HPV test. The clinical sensitivity and specificity of using
FTA card and the HPVIR test was not inferior to that of
LBC samples and Cobas® HPV test, using the inter-
national thresholds of a relative sensitivity = 90% and
specificity = 98% [2]. Cervical samples applied to an FTA
card and analysed with HPVIR showed intra-laboratory
reproducibility close to 1, and a higher inter-laboratory
agreement than the recommended 87% [2]. The corre-
sponding kappa values were much higher than 0.5 for
both intra- and inter-laboratory comparisons [2].
Comparisons of HPV test results
Among women without disease, 3.6% (29/799) showed
discordant HPV test results between the HPVIR and the
Cobas® HPV test, and 89.7% (26/29) of discordant sam-
ples were HPV positive only with the Cobas® HPV test.
In 88.5% (23/26) of these discordant samples, the geno-
type was indicated as ‘Other HPV‘by the Cobas® HPV
test. For two of these samples, the linear array did not
indicate the HPV type, possibly due to limited amounts
of material. Of the 21 samples that were Cobas® HPV
positive but HPVIR negative and for which the linear
array resulted in an HPV genotype, 6 of the samples had
HPV66 and 68, types not included in the HPVIR test.
HPV66 is a genotype that was previously considered
high-risk, but recent studies indicate that it has low or
no oncogenic properties [22]. The oncogenic properties
of the HPV68 genotype have also been questioned and it
has recently been proposed to be an intermediate risk
genotype [23]. Three of the samples contained non-
hrHPV types to which the Cobas® HPV cross-hybridizes.
The category ‘Other HPV‘in the Cobas® HPV test has
previously been reported to show cross-reactivity with
low-risk HPV genotypes. A study of 5022 women com-
paring two other commercial hrHPV tests with Cobas®
HPV showed that about 25% of the samples that were
positive with the Cobas® HPV test represented cross-re-
activity with low-risk genotypes [24]. Thus, the category
‘Other HPV‘can include some false positive results. The
higher incidence of HPV in women < CIN2 when using
Cobas® HPV test compared to HPVIR test would in-
crease colposcopy resources and costs for the screening
program, as well as worry some women that will be ex-
posed to unnecessary examination.
The performance of HPVIR and Cobas® HPV was similar
in the group of cases used to estimate the sensitivity, were
none of the samples was HPV negative and 89.6% (60/67)
had HPV positive results. Three samples were positive only
using the Cobas® HPV test (3 CIN3, 2 HPV16 and 1 non
HPV16/18) and 4 samples (2 CIN2 and 2 CIN3, 1 HPV16
and 3 non HPV16/18) were positive only using the HPVIR
test. Our results confirms that HPV16 or 18 occurs in more
than 50% of women with high-risk lesions [25].
Sample collection media
In addition to comparing the HPVIR test against a reference
test, we used different sampling media. The internationally
widely used standardized method ThinPrep® LBC for the
Cobas® HPV test was compared to the indicating FTA
Elute™ micro card, the dry sampling medium for the HPVIR
test. Since two different samples were collected from each
woman, the sampling order may affect the results of the
HPV assay. There was no significant difference in HPV posi-
tivity between the samples collected first and second for ei-
ther of the tests. A screening method using a dry storage
media as the indicating FTA Elute™ micro card in combin-
ation with a highly sensitive HPV test provides an effective
method for primary cervical cancer screening. This strategy
will present a low cost and high throughput alternative, in
addition to being easily adapted for self-sampling. HPV test-
ing using vaginal self-sampling on FTA card has been shown
to be as reliable as assisted cervical sampling [14, 15]. We
have recently shown that repeating the self-sampling and
HPV test for women that were HPV positive in the screen-
ing sample after 4–6months, in order to identify women
with persistent infections, can results in more than two-fold
higher detection rate of CIN2 + -lesions, compared to cy-
tology screening [14, 15]. This method could decrease both
incidence and mortality in cervical cancer, as early detection
and treatment remains the most effective means of
prevention. By using additional methods of triage of hrHPV
positive women, such as methylation status or HPV viral
load, the specificity of the screening strategy could be im-
proved, resulting in fewer unnecessary colposcopies and
treatments [23].
Intra-laboratory reproducibility and inter-laboratory
agreement
The inter- and inter-laboratory analyses was based on
558 samples collected in South Africa selected on the
Table 3 Inter-laboratory agreement of the HPVIR test
Cape Town Lab
Uppsala Lab HPV positive HPV negative Total
HPV positive 240 3 243
HPV negative 32 283 315
Total 272 286 558
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criterion that at least 30% had previously tested HPV
positive with the reference test HC2. In both the intra-
and inter-laboratory analyses the lower confidence
bounds were > 87% with kappa values > 0.5 and, the re-
sults complied well with the guidelines. The HPVIR test
has been validated yearly using the WHO panel with
100% proficiency. The result from inter-laboratory test-
ing showed that the HPVIR method is robust enough
and can be operated reliably at other sites than Uppsala.
Conclusions
Cervical samples applied on FTA card and analysed with
HPVIR test shows similar sensitivity and specificity as
LBC samples analysed with the Cobas® HPV test, and
thereby fulfil the requirements of the international
guidelines for an HPV test to be used for primary cer-
vical cancer screening. The use of the FTA cards and
HPVIR has the advantage that it is both easily used for
self-sampling and report extended HPV genotyping
results.
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